Phase II study of S-1, a novel oral fluoropyrimidine, and biweekly administration of docetaxel for previously treated advanced non-small-cell lung cancer |
| |
Authors: | Yasunari Oki Takashi Hirose Toshimitsu Yamaoka Sojiro Kusumoto Takao Shirai Tomohide Sugiyama Kentaro Okuda Masanao Nakashima Yasunori Murata Tohru Ohmori Mitsuru Adachi |
| |
Institution: | 1. Division of Respiratory Medicine and Allergology, Department of Internal Medicine, Showa University School of Medicine, 1-5-8 Hatanodai, Shinagawa, Tokyo, 142-8666, Japan 2. Institute of Molecular Oncology, Showa University School of Medicine, 1-5-8 Hatanodai, Shinagawa, Tokyo, 142-8666, Japan
|
| |
Abstract: | Purpose We examined the safety and efficacy of the combination of S-1 and biweekly docetaxel in patients with previously treated advanced non-small-cell lung cancer (NSCLC). Methods Patients with previously treated advanced NSCLC were eligible if they had a performance status of 2 or less, were 80?years or younger, and had adequate organ function. Forty-nine patients (38 men and 11 women; median age, 66?years; range 43?C79?years) were enrolled. Patients were treated with the combination of 80?mg/m2 per day of S-1 for 14 consecutive days and 35?mg/m2 of docetaxel on days 1 and 15 every 4?weeks. Results The overall response rate was 16.3% (95% confidence interval, 7.6?C30.5%). The disease-control rate was 49.0% (95% confidence interval, 34.4?C63.7%). The median survival time after this treatment was 9?months (range 1?C22?months). The median progression-free survival time was 3?months (range 1?C11?months). Response rates and survival times did not differ significantly according to the histological type. Grade 3?C5 toxicities included neutropenia in 51.0% of patients, thrombocytopenia in 2.0%, anemia in 20.4%, infection in 24.5%, anorexia in 12.2%, diarrhea in 14.3%, nausea in 6.1%, and dehydration in 4.2%. There was 1 treatment-related death due to severe anorexia, stomatitis, diarrhea, and, as consequence, dehydration. Conclusions The combination of S-1 and biweekly docetaxel is an acceptable therapeutic option in patients with previously treated advanced NSCLC regardless of the histological type. |
| |
Keywords: | |
本文献已被 SpringerLink 等数据库收录! |
|